Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter-Reference-Cited by-同舟云学术

Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

Published:2014-04-24 Issue:7 Volume:10 Page:1935-1948
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

van Els Cécile¹,Mjaaland Siri²,Næss Lisbeth²,Sarkadi Julia³,Gonczol Eva³,Smith Korsholm Karen⁴,Hansen Jon⁴,de Jonge Jørgen¹,Kersten Gideon⁵⁶,Warner Jennifer⁷,Semper Amanda⁷,Kruiswijk Corine⁵,Oftung Fredrik²

Affiliation:

1. National Institute for Public Health and the Environment; Bilthoven, the Netherlands

2. Norwegian Institute of Public Health; Oslo, Norway

3. National Center for Epidemiology (NCE); Budapest, Hungary

4. Statens Serum Institut; Copenhagen, Denmark

5. Institute for Translational Vaccinology; Bilthoven, the Netherlands

6. Leiden Academic Center for Drug Research; University of Leiden; The Netherlands

7. Public Health England; Porton Down, England

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.4161/hv.28639

Reference148 articles.

1. Climate and Vectorborne Diseases

2. Climate change and infectious diseases in Europe

3. WHO. Severe acute respiratory syndrome (SARS): Status of the outbreak and lessons for the immediate future. 2003. Available from: http://www.who.int/csr/don/2003_04_11/en/

4. Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus

5. WHO. Evolution of a pandemic A(H1N1) 2009. 2013.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay;Vaccines;2022-09-14

2. The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe;COVID;2021-06-26

3. Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients;Viruses;2021-05-26

4. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need;Signal Transduction and Targeted Therapy;2021-02-02

5. Malaria vaccines: facing unknowns;F1000Research;2020-04-27